4//SEC Filing
ARCA biopharma, Inc. 4
Accession 0001209191-16-127436
$ORKACIK 0000907654operating
Filed
Jun 12, 8:00 PM ET
Accepted
Jun 13, 5:24 PM ET
Size
10.5 KB
Accession
0001209191-16-127436
Insider Transaction Report
Form 4
Ozeroff Christopher David
EVP & General Counsel
Transactions
- Award
Stock Option (right to buy)
2016-06-09+30,200→ 30,200 totalExercise: $3.30Exp: 2026-06-08→ Common Stock (30,200 underlying) - Award
Stock Option (right to buy)
2016-06-09+14,800→ 14,800 totalExercise: $3.30Exp: 2026-06-08→ Common Stock (14,800 underlying)
Holdings
- 19,585
Common Stock
Footnotes (3)
- [F1]Includes (i) remaining 3,571 previously reported shares issued as RSUs under the Plan that vest on 9/17/16, (ii) remaining 2,443 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning on 2/27/17, and (iii) 2,290 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning 4/2/17, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 11,281 previously reported shares of common stock held directly.
- [F2]Grant to the Reporting Person of a stock option under the Plan, vesting in 36 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested.
- [F3]Grant to the Reporting Person of a stock option under the Plan, vesting upon achievement of certain pre-specified corporate milestones related to enrollment for the GENETIC-AF clinical trial, and the timing and outcome of the interim data analysis by that trial's Data and Safety Monitoring Board, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. If the corporate milestones are not achieved, the Option will be cancelled. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested.
Documents
Issuer
ARCA biopharma, Inc.
CIK 0000907654
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000907654
Filing Metadata
- Form type
- 4
- Filed
- Jun 12, 8:00 PM ET
- Accepted
- Jun 13, 5:24 PM ET
- Size
- 10.5 KB